Sensei Biotherapeutics Inc

Research Sensei Biotherapeutics Inc (SNSE) on Bullrun: market cap USD 28.85M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 28.85M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 21.09M-USD 20.47Mn/a-16.72USD 8.67MUSD 1.51MUSD 18.59M
FY2024USD 0-USD 30.16M-USD 24.82Mn/a-24.01USD 9.99MUSD 3.85MUSD 38.39M
FY2023USD 0-USD 34.10M-USD 32.20Mn/a-1.22USD 13.01MUSD 6.21MUSD 64.90M
FY2022USD 0-USD 48.59M-USD 39.35Mn/a-1.58USD 17.80MUSD 8.03MUSD 103.41M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-06-26USD 28.85Mn/an/an/a
20252025-12-31USD 13.45Mn/an/an/a
20242024-12-31USD 12.34Mn/an/an/a
20232023-12-29USD 17.30Mn/an/an/a
20222022-12-30USD 45.77Mn/an/an/a
20212021-12-31USD 177.54Mn/an/an/a

About Sensei Biotherapeutics Inc

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sensei Biotherapeutics Inc's market cap?

Sensei Biotherapeutics Inc's market capitalization is USD 28.85M.

What does Sensei Biotherapeutics Inc do?

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.